Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adicet Bio, Inc. - Common Stock (NQ:ACET)

7.310 +0.060 (+0.83%)
Streaming Delayed Price Updated: 2:55 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Adicet Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Present at Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Present at Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Present at Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Participate in Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
From Adicet Bio, Inc.
Via Business Wire
News headline image
Adicet Bio to Participate in Guggenheim 2022 Oncology Conference
From Adicet Bio, Inc.
Via Business Wire
News headline image
Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
From Twist Bioscience Corporation and Adicet Bio
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.